Skip to main
DCGO

DocGo (DCGO) Stock Forecast & Price Target

DocGo (DCGO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DocGo is expected to experience strong revenue growth in the coming years, driven by the company's Mobile Health Services segment, particularly in the United States. The acquisition of SteadyMD enhances the company's virtual care capabilities and offers potential for higher margins. However, the company's path to profitability remains uncertain, and it will need to carefully manage operating expenses to achieve its target. While the current valuation may seem low, it is justified by the company's performance and outlook.

Bears say

DocGo is discontinuing coverage as the company has a history of underperforming their guidance and facing headwinds in their core medical transportation business. Despite some positive growth in key lines of business, there are concerns about the sustainability of revenue streams, including the potential for a decline in testing revenue after the COVID-19 pandemic. The company's recent SPAC merger and hesitancy from investors regarding the durability of their revenue stream have also contributed to a discounted valuation. Additionally, while guidance has been raised for the upcoming year, a modest EBITDA loss is still projected and there are concerns about the company's ability to scale their go-forward Mobile Health business and improve profitability. Overall, a "show me" stance is warranted at this time.

DocGo (DCGO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DocGo (DCGO) Forecast

Analysts have given DocGo (DCGO) a Buy based on their latest research and market trends.

According to 4 analysts, DocGo (DCGO) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DocGo (DCGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.